Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4

Cell Metabolism

Volumn 25, Issue 5, 2017, Pages 1063-1074.e3

  Cavallari, Joseph F ^a   Fullerton, Morgan D ^a   Duggan, Brittany M ^a   Foley, Kevin P ^a   Denou, Emmanuel ^a   Smith, Brennan K ^a   Desjardins, Eric M ^a   Henriksbo, Brandyn D ^a   Kim, Kalvin J ^a   Tuinema, Brian R ^a   Stearns, Jennifer C ^a,b   Prescott, David ^c   Rosenstiel, Philip ^d   Coombes, Brian K ^a,b   Steinberg, Gregory R ^a   Schertzer, Jonathan D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

diabetes; endotoxemia; glucose; inflammation; insulin resistance; microbiome; microbiota; obesity; peptidoglycan

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GLUCOSE; INTERFERON REGULATORY FACTOR 4; MIFAMURTIDE; MURAMYL DIPEPTIDE; PEPTIDOGLYCAN; CARD15 PROTEIN, MOUSE; CARD4 PROTEIN, MOUSE; CASPASE RECRUITMENT DOMAIN PROTEIN 4; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL WALL; CONTROLLED STUDY; ENDOTOXEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; MOUSE MUTANT;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; ENDOTOXEMIA; INFLAMMATION; INSULIN RESISTANCE; INTERFERON REGULATORY FACTORS; MICE, INBRED C57BL; MICE, OBESE; MICROBIOTA; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; OBESITY;

EID: 85018584588     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.03.021     Document Type: Article

References (50)

1. Ahyi, A.-N.N., Chang, H.-C., Dent, A.L., Nutt, S.L., Kaplan, M.H., IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J. Immunol. 183 (2009), 1598–1606.
2. Amar, J., Chabo, C., Waget, A., Klopp, P., Vachoux, C., Bermúdez-Humarán, L.G., Smirnova, N., Bergé, M., Sulpice, T., Lahtinen, S., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 3 (2011), 559–572.
3. Bruchard, M., Rebé, C., Derangère, V., Togbé, D., Ryffel, B., Boidot, R., Humblin, E., Hamman, A., Chalmin, F., Berger, H., et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat. Immunol. 16 (2015), 859–870.
4. Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 (2015), 577–591.
5. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
6. Chi, W., Dao, D., Lau, T.C., Henriksbo, B.D., Cavallari, J.F., Foley, K.P., Schertzer, J.D., Bacterial peptidoglycan stimulates adipocyte lipolysis via NOD1. PLoS ONE, 9, 2014, e97675.
7. Cicenia, A., Scirocco, A., Carabotti, M., Pallotta, L., Marignani, M., Severi, C., Postbiotic activities of lactobacilli-derived factors. J. Clin. Gastroenterol. 48:Suppl 1 (2014), S18–S22.
8. Clarke, T.B., Davis, K.M., Lysenko, E.S., Zhou, A.Y., Yu, Y., Weiser, J.N., Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16 (2010), 228–231.
9. Denou, E., Lolmède, K., Garidou, L., Pomie, C., Chabo, C., Lau, T.C., Fullerton, M.D., Nigro, G., Zakaroff-Girard, A., Luche, E., et al. Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. EMBO Mol. Med. 7 (2015), 259–274.
10. Eguchi, J., Wang, X., Yu, S., Kershaw, E.E., Chiu, P.C., Dushay, J., Estall, J.L., Klein, U., Maratos-Flier, E., Rosen, E.D., Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 13 (2011), 249–259.
11. Eguchi, J., Kong, X., Tenta, M., Wang, X., Kang, S., Rosen, E.D., Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 62 (2013), 3394–3403.
12. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., Guiot, Y., Derrien, M., Muccioli, G.G., Delzenne, N.M., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 110 (2013), 9066–9071.
13. Fernández-Real, J.M., Pérez del Pulgar, S., Luche, E., Moreno-Navarrete, J.M., Waget, A., Serino, M., Sorianello, E., Sánchez-Pla, A., Pontaque, F.C., Vendrell, J., et al. CD14 modulates inflammation-driven insulin resistance. Diabetes 60 (2011), 2179–2186.
14. Fogler, W.E., Fidler, I.J., Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Int. J. Immunopharmacol. 9 (1987), 141–150.
15. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr. Drugs 12 (2010), 141–153.
16. Fritz, J.H., Le Bourhis, L., Sellge, G., Magalhaes, J.G., Fsihi, H., Kufer, T.A., Collins, C., Viala, J., Ferrero, R.L., Girardin, S.E., Philpott, D.J., Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26 (2007), 445–459.
17. Girardin, S.E., Boneca, I.G., Carneiro, L.A., Antignac, A., Jéhanno, M., Viala, J., Tedin, K., Taha, M.K., Labigne, A., Zähringer, U., et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300 (2003), 1584–1587.
18. Girardin, S.E., Boneca, I.G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., Philpott, D.J., Sansonetti, P.J., Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278 (2003), 8869–8872.
19. Hedl, M., Li, J., Cho, J.H., Abraham, C., Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc. Natl. Acad. Sci. USA 104 (2007), 19440–19445.
20. Henriksbo, B.D., Lau, T.C., Cavallari, J.F., Denou, E., Chi, W., Lally, J.S., Crane, J.D., Duggan, B.M., Foley, K.P., Fullerton, M.D., et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63 (2014), 3742–3747.
21. Hergott, C.B., Roche, A.M., Tamashiro, E., Clarke, T.B., Bailey, A.G., Laughlin, A., Bushman, F.D., Weiser, J.N., Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis. Blood 127 (2016), 2460–2471.
22. Honma, K., Udono, H., Kohno, T., Yamamoto, K., Ogawa, A., Takemori, T., Kumatori, A., Suzuki, S., Matsuyama, T., Yui, K., Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc. Natl. Acad. Sci. USA 102 (2005), 16001–16006.
23. Kager, L., Pötschger, U., Bielack, S., Review of mifamurtide in the treatment of patients with osteosarcoma. Ther. Clin. Risk Manag. 6 (2010), 279–286.
24. Khan, M.T., Nieuwdorp, M., Bäckhed, F., Microbial modulation of insulin sensitivity. Cell Metab. 20 (2014), 753–760.
25. Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., Terasawa, K., Kashihara, D., Hirano, K., Tani, T., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun., 4, 2013, 1829.
26. Kobayashi, K., Inohara, N., Hernandez, L.D., Galán, J.E., Núñez, G., Janeway, C.A., Medzhitov, R., Flavell, R.A., RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416 (2002), 194–199.
27. Kong, X., Banks, A., Liu, T., Kazak, L., Rao, R.R., Cohen, P., Wang, X., Yu, S., Lo, J.C., Tseng, Y.-H., et al. IRF4 is a key thermogenic transcriptional partner of PGC-1α. Cell 158 (2014), 69–83.
28. Kristensen, N.B., Bryrup, T., Allin, K.H., Nielsen, T., Hansen, T.H., Pedersen, O., Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med., 8, 2016, 52.
29. Macho Fernandez, E., Valenti, V., Rockel, C., Hermann, C., Pot, B., Boneca, I.G., Grangette, C., Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 60 (2011), 1050–1059.
30. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
31. Mittrücker, H.W., Matsuyama, T., Grossman, A., Kündig, T.M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P.S., Mak, T.W., Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275 (1997), 540–543.
32. Nardin, A., Lefebvre, M.-L., Labroquère, K., Faure, O., Abastado, J.-P., Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 6 (2006), 123–133.
33. Negishi, H., Ohba, Y., Yanai, H., Takaoka, A., Honma, K., Yui, K., Matsuyama, T., Taniguchi, T., Honda, K., Negative regulation of Toll-like-receptor signaling by IRF-4. Proc. Natl. Acad. Sci. USA 102 (2005), 15989–15994.
34. Oksanen, J., Blanchet, F.G., Friendly, M., Kindt, R., Legendre, P., McGlinn, D., Minchin, P.R., O'Hara, R.B., Simpson, G.L., Solymos, P., Stevens, M.H.H., Szoecs, E., and Wagner, H. (2015). vegan: Community Ecology Package (CRAN).
35. Passlick, B., Labeta, M.O., Izbicki, J.R., Ostertag, P., Löffler, T., Siebeck, M., Pichlmeier, U., Schweiberer, L., Ziegler-Heitbrock, H.W., Prevention of experimental endotoxin shock by a monocyte activator. Antimicrob. Agents Chemother. 39 (1995), 2535–2540.
36. Patel, R.M., Denning, P.W., Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence?. Clin. Perinatol. 40 (2013), 11–25.
37. Perry, R.J., Peng, L., Barry, N.A., Cline, G.W., Zhang, D., Cardone, R.L., Petersen, K.F., Kibbey, R.G., Goodman, A.L., Shulman, G.I., Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534 (2016), 213–217.
38. Pomié, C., Blasco-Baque, V., Klopp, P., Nicolas, S., Waget, A., Loubières, P., Azalbert, V., Puel, A., Lopez, F., Dray, C., et al. Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia. Mol. Metab. 5 (2016), 392–403.
39. Postic, C., Shiota, M., Niswender, K.D., Jetton, T.L., Chen, Y., Moates, J.M., Shelton, K.D., Lindner, J., Cherrington, A.D., Magnuson, M.A., Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274 (1999), 305–315.
40. Reijnders, D., Goossens, G.H., Hermes, G.D.A., Neis, E.P.J.G., van der Beek, C.M., Most, J., Holst, J.J., Lenaerts, K., Kootte, R.S., Nieuwdorp, M., et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 24 (2016), 63–74.
41. Schertzer, J.D., Tamrakar, A.K., Magalhães, J.G., Pereira, S., Bilan, P.J., Fullerton, M.D., Liu, Z., Steinberg, G.R., Giacca, A., Philpott, D.J., Klip, A., NOD1 activators link innate immunity to insulin resistance. Diabetes 60 (2011), 2206–2215.
42. Simon, M.-C., Strassburger, K., Nowotny, B., Kolb, H., Nowotny, P., Burkart, V., Zivehe, F., Hwang, J.-H., Stehle, P., Pacini, G., et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care 38 (2015), 1827–1834.
43. Tamrakar, A.K., Schertzer, J.D., Chiu, T.T., Foley, K.P., Bilan, P.J., Philpott, D.J., Klip, A., NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 151 (2010), 5624–5637.
44. Thaiss, C.A., Itav, S., Rothschild, D., Meijer, M., Levy, M., Moresi, C., Dohnalová, L., Braverman, S., Rozin, S., Malitsky, S., et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature 540 (2016), 1–27.
45. Turnbaugh, P.J., Ridaura, V.K., Faith, J.J., Rey, F.E., Knight, R., Gordon, J.I., The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med., 1, 2009, 6ra14.
46. Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., Ravussin, E., Stephens, J.M., Dixit, V.D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
47. Watanabe, T., Asano, N., Murray, P.J., Ozato, K., Tailor, P., Fuss, I.J., Kitani, A., Strober, W., Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118 (2008), 545–559.
48. Watanabe, T., Asano, N., Meng, G., Yamashita, K., Arai, Y., Sakurai, T., Kudo, M., Fuss, I.J., Kitani, A., Shimosegawa, T., et al. NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6. Mucosal Immunol. 7 (2014), 1312–1325.
49. Williams, J.W., Tjota, M.Y., Clay, B.S., Vander Lugt, B., Bandukwala, H.S., Hrusch, C.L., Decker, D.C., Blaine, K.M., Fixsen, B.R., Singh, H., et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat. Commun., 4, 2013, 2990.
50. Wolf, A.J., Reyes, C.N., Liang, W., Becker, C., Shimada, K., Wheeler, M.L., Cho, H.C., Popescu, N.I., Coggeshall, K.M., Arditi, M., Underhill, D.M., Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell 166 (2016), 624–636.